D Ross Camidge

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers
    D Ross Camidge
    Developmental Therapeutics Program, University of Colorado Cancer Center, Denver Thoracic Oncology Program, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    Clin Lung Cancer 10:262-72. 2009
  2. ncbi The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer
    D Ross Camidge
    Developmental Therapeutics and Thoracic Malignancies Programs, University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA
    Clin Lung Cancer 8:413-9. 2007
  3. ncbi A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
  4. ncbi A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies
    D Ross Camidge
    Department of Medical Oncology, University of Colorado, Denver, Colorado, USA
    Clin Cancer Res 16:1256-63. 2010
  5. ncbi Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    D Ross Camidge
    Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Expert Opin Biol Ther 8:1167-76. 2008
  6. ncbi Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
  7. ncbi Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
  8. ncbi Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer
    D Ross Camidge
    University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4486-94. 2012
  9. ncbi Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    D Ross Camidge
    Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P O Box 6510, Mail Stop F 706, Aurora, CO 80045 0508, USA
    J Thorac Oncol 6:774-80. 2011
  10. ncbi Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Cancer 118:5302-9. 2012

Detail Information

Publications33

  1. ncbi The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers
    D Ross Camidge
    Developmental Therapeutics Program, University of Colorado Cancer Center, Denver Thoracic Oncology Program, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    Clin Lung Cancer 10:262-72. 2009
    ..Explorations of aspects of ligands, binding proteins, receptors, and receptor substrates are all ongoing to identify potential biomarkers predictive of benefit from IGF axis intervention...
  2. ncbi The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer
    D Ross Camidge
    Developmental Therapeutics and Thoracic Malignancies Programs, University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA
    Clin Lung Cancer 8:413-9. 2007
    ..Trials of DR4/5-directed therapies in combination with standard first-line chemotherapy for non-small-cell lung cancer are under way...
  3. ncbi A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  4. ncbi A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies
    D Ross Camidge
    Department of Medical Oncology, University of Colorado, Denver, Colorado, USA
    Clin Cancer Res 16:1256-63. 2010
    ..This first-in-human study assessed the safety, tolerability, pharmacokinetics, and any early evidence of efficacy of PRO95780 in patients with advanced malignancies...
  5. ncbi Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    D Ross Camidge
    Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Expert Opin Biol Ther 8:1167-76. 2008
    ..Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2)...
  6. ncbi Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
    ....
  7. ncbi Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  8. ncbi Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer
    D Ross Camidge
    University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4486-94. 2012
    ..Increased copy numbers of fused and rearranged signals also occur. Here, correlations are explored between the percentage of ALK+ cells and signal copy number and their association with response to ALK inhibition...
  9. ncbi Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    D Ross Camidge
    Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P O Box 6510, Mail Stop F 706, Aurora, CO 80045 0508, USA
    J Thorac Oncol 6:774-80. 2011
    ..To explore whether the progression-free survival (PFS) with pemetrexed differs between anaplastic lymphoma kinase (ALK)-positive and other major molecular subtypes of non-small cell lung cancer...
  10. ncbi Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Cancer 118:5302-9. 2012
    ..The objective of this study was to document the differences in testosterone (T) levels between crizotinib-treated and noncrizotinib-treated patients with metastatic nonsmall cell lung cancer (NSCLC)...
  11. ncbi Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma
    D Ross Camidge
    University of Colorado Cancer Center, Mail Stop F704, 1665 Aurora Court, ACP Room 2256, Aurora, CO 80045, USA
    Cancer Chemother Pharmacol 71:307-19. 2013
    ..To determine the maximum tolerated dose (MTD), safety and tolerability of sunitinib plus pemetrexed and cisplatin for advanced solid malignancies...
  12. ncbi Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer
    Neha P Amin
    Departments of Radiation Oncology, University of Colorado, School of Medicine, Aurora, Colorado, USA
    J Thorac Oncol 6:1553-62. 2011
    ..This study compared radiation therapy (RT) plans based on pre- and postchemotherapy computed tomography (CT) scans of patients with SCLC to estimate the reduced risk of radiation pneumonitis (RP) after receiving chemotherapy...
  13. ncbi New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Robert C Doebele
    University of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA
    Lung Cancer 69:1-12. 2010
    ....
  14. ncbi A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 29:3567-73. 2011
    ....
  15. ncbi Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
    Kurtis D Davies
    Division of Medical Oncology, University of Colorado, MS 8117, 12801 E 17th Ave, Aurora, CO 80045, USA
    Clin Cancer Res 18:4570-9. 2012
    ..In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets...
  16. ncbi Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado
    Cancer 119:1467-77. 2013
    ..Cancer 2013. © 2012 American Cancer Society...
  17. ncbi Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    D Ross Camidge
    University of Colorado Denver, Aurora, CO, USA
    Lancet Oncol 13:1011-9. 2012
    ..We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study...
  18. ncbi Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Robert C Doebele
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA
    Clin Cancer Res 18:1472-82. 2012
    ..This study aimed to define molecular mechanisms of resistance to crizotinib in patients with ALK(+) non-small cell lung cancer (NSCLC)...
  19. ncbi A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
    Qing Zhou
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Invest New Drugs 29:340-6. 2011
    ..This first-in-human phase I study evaluated the tolerability, pharmacokinetics and preliminary evidence of activity of ENMD-1198 in advanced cancer patients...
  20. ncbi Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
    Stephen Leong
    Division of Medical Oncology, University of Colorado Health Sciences Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 27:4413-21. 2009
    ....
  21. ncbi A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    Andrew Weickhardt
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 7:419-26. 2012
    ....
  22. ncbi Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis
    Kyle E Rusthoven
    Department of Radiation Oncology, University of Colorado Comprehensive Cancer Center, Denver, USA
    Acta Oncol 48:578-83. 2009
    ..We evaluate the POF in this setting to estimate the potential value of consolidative stereotactic body radiation therapy (SBRT)...
  23. ncbi Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC
    Scott A Kono
    Thoracic Oncology Program, University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA
    Oncology (Williston Park) 23:424-9. 2009
    ....
  24. ncbi Targeted manipulation of apoptosis in cancer treatment
    Justin A Call
    Developmental Therapeutics and Gastrointestinal Malignancies Programs, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA
    Lancet Oncol 9:1002-11. 2008
    ..This Review summarises the rationale for direct manipulation of various elements of apoptosis and describes agents that are currently under investigation in early-phase clinical trials in many different cancer types...
  25. ncbi Treating ALK-positive lung cancer--early successes and future challenges
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA ross camidge ucdenver edu
    Nat Rev Clin Oncol 9:268-77. 2012
    ....
  26. ncbi Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
    D Ross Camidge
    Division of Medical Oncology and Department of Pathology, University of Colorado Denver, 1665 North Ursula Street, Aurora, CO 80045 0508, USA
    Clin Cancer Res 16:5581-90. 2010
    ..We explored the heterogeneity basis, the requirements for accurately determining ALK FISH positivity, and the effect of enriching the tested population using clinical and molecular factors...
  27. ncbi Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli
    Lian Zhang
    Department of Pharmacology, University of Colorado, School of Medicine, Aurora, CO, USA
    Clin Cancer Res 16:4478-89. 2010
    ....
  28. ncbi The intersection between cannabis and cancer in the United States
    Daniel W Bowles
    Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Crit Rev Oncol Hematol 83:1-10. 2012
    ....
  29. ncbi Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making
    Todd M Erickson
    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Thorac Oncol 3:1353-5. 2008
    ....
  30. ncbi From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer
    Glen J Weiss
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncology (Williston Park) 20:1515-24; discussion 1524-5, 1530, 1535. 2006
    ..Together, these developments have moved us away from the nihilism of 20 years ago into an era of unprecedented optimism in taking on the many remaining challenges of managing NSCLC in the 21st century...
  31. ncbi Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Lawrence H Einhorn
    Indiana Cancer Pavilion, Indianapolis, Indiana, USA
    J Thorac Oncol 3:545-55. 2008
  32. ncbi A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers
    D Ross Camidge
    Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
    Cancer Chemother Pharmacol 60:391-8. 2007
    ..The pharmacokinetic profile of AZD5438 determined within this study will be used to guide the time-points for PD analysis within the planned PD study...
  33. ncbi Dynamic and modern: bringing the ethics of phase I trials up to date
    D Ross Camidge
    J Clin Oncol 24:5178-9; author reply 5179-80. 2006